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Abstract
Background—The use of methylprednisolone (MP) and other corticosteroids for the treatment of
acute liver allograft rejection is associated with severe toxicities in non-target tissues. Therefore,
selective delivery of MP to the liver may improve its efficacy and alleviate its side effects. We
investigated the effects of a novel liver-targeted dextran prodrug of MP (DMP) in an orthotopic rat
liver transplantation (OLT) model.
Methods—The model consisted of a high responder rejection strain combination (Dark Agouti
donors and Lewis recipients). Liver recipients were intravenously administered saline or a single
subtherapeutic dose of MP (5 mg/kg) as the parent drug (MP) or its prodrug (DMP). Different groups
were then monitored for graft survival or euthanized 5 or 9 days post-transplantation. Plasma
chemistry, including alkaline phosphatase and bilirubin, allograft histology, and survival duration
were determined.
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Results—Untreated recipients exhibited elevated plasma levels of liver injury markers, progressive
portal and venous inflammation and cellular infiltration in liver allografts, and a mean graft survival
time (MST) of 10.5 days. MP treatment did not alter any of these parameters. In contrast, a single
dose of DMP resulted in a decrease in plasma levels of liver injury markers, a decrease in histological
grade of rejection on day 5, and a substantial increase in MST (27.5 days).
Conclusions—These results demonstrate attenuation of acute rejection following local (allograft)
immunosuppression with a single subtherapeutic dose of MP delivered as a liver-targeted prodrug.
Dextran prodrugs may be useful for selective delivery of immunosuppressants to the liver following
liver transplantation.
Keywords
Dextran prodrugs; Methylprednisolone; Local immunosuppression; Targeted delivery
1This work was supported in part by an unrestricted research fund generated from research contracts to RM and by a grant from the
National Institute of General Medical Sciences of NIH (R01 GM069869-01A2).
7.Address for Correspondence: Reza Mehvar, Ph.D., School of Pharmacy, Texas Tech University Health Sciences Center, 1300 S.
Coulter, TX 79106, Telephone: (806) 356-4015 Ext 337, Fax: (806) 356-4034, E-Mail: reza.mehvar@ttuhsc.edu.
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ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; DMP,
dextran methylprednisolone succinate; IL-2, interleukin-2; MP, methylprednisolone; OLT,
orthotopic rat liver transplantation; RAI, rejection activity index; TNF-α, tumor necrosis factor-α

INTRODUCTION
Liver transplantation is currently the treatment of choice for many types of acute or chronic
liver diseases (1). Advances in immunosuppressive therapy have played a major role in the
success of liver transplantation (2). However, currently available drugs cause indiscriminate
systemic immunosuppression and prevent graft rejection at the expense of various side effects,
resulting in considerable morbidity and mortality (3). Delivery of these drugs locally to the
allograft, thereby decreasing systemic exposure, has been proposed as a potential approach to
overcome some of these problems (4,5). Moreover, selective immunosuppression in the graft
necessitates lower drug doses, potentially reducing side effects (6).
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The strategy of local immunosuppression at the graft site has been shown by several
investigators to be superior to non-specific systemic immunosuppression (6–11). Initial
attempts at local immunosuppression focused on local application of drugs via intra-arterial
infusions using delivery systems like catheters and mini-pumps (6,7). However, these
procedures are invasive, causing infections and thrombotic complications, and rarely are
applicable clinically (10). Moreover, the local immunosuppressive efficacy in these instances
is dependent on the pharmacokinetics of these drugs (4,6), and therefore not generally
applicable to all immunosuppressive agents (5). To overcome these problems, we proposed
(12,13) the use of dextrans as macromolecular carriers for selective delivery of
immunosuppressive drugs to the liver for liver transplantation.
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Dextrans are glucose polymers that have long been used as plasma volume expanders (14,
15). We coupled methylprednisolone (MP), as a model immunosuppressive drug, to a 70 kDa
dextran via a succinate linker to produce a dextran-MP prodrug (DMP) (16). We further
demonstrated that DMP accumulates selectively in the liver and spleen, where it slowly
regenerates the active drug MP (17). This selective accumulation in the liver and spleen is
reflective of the property of the macromolecular/polymeric carrier dextran (18). Furthermore,
DMP was demonstrated (19,20) to have a more intense and sustained systemic (spleen) and
local (liver) immunosuppressive effect, compared with equimolar doses of MP. Given these
superior pharmacokinetic and pharmacodynamic properties, we hypothesized that DMP
treatment decreases liver allograft rejection and, consequently, improves survival even at subtherapeutic doses of MP. Therefore, an orthotopic rat liver transplantation (OLT) model in a
high responder rejection strain combination (Dark Agouti liver donors and Lewis recipients)
was performed to study the effects of MP and DMP treatment on acute allograft rejection.

MATERIALS AND METHODS
All procedures involved animals were approved by the Texas Tech University Health Sciences
Center Animal Care and Use Committee and were in accordance with the guidelines set by the
National Institutes of Health (publication no. 85–23, revised 1985, Bethesda, MD).
Orthotopic Rat Liver Transplantation (OLT)
Inbred male Dark Agouti (DA, RT1av1) and Lewis (LEW, RT1) rats served as liver donors and
recipients, respectively. All surgical procedures were performed under aseptic conditions using
isoflurane anesthesia delivered in an oxygen:nitrous oxide mixture. A non-arterialized OLT
Transplantation. Author manuscript; available in PMC 2006 June 27.
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was performed according to Kamada’s technique (21), as modified by Tsuchimoto et al. (22).
In the donor rats (225–250 g), the right adrenal, right renal, gastro-duodenal, left phrenic, and
splenic veins were ligated. The liver was perfused via the portal vein with 10 mL of cold
University of Wisconsin (UW) solution (Viaspan, Dupont Pharma Wilmington, DE) prior to
liver isolation. The excised liver was then immersed in cold UW solution, and cuffs were
mounted on the portal vein (PV), infrahepatic vena cava (IHVC), and the suprahepatic vena
cava (SHVC). The recipient rats (250–275 g) were anesthetized, and a long midline incision
was made on the abdomen. The hepatic artery was doubly ligated and divided. The bile duct
was severed at the junction of the hepatic ducts. The recipient liver was mobilized, the PV and
IHVC were cross clamped, and the SHVC, including a part of the diaphragm, was clamped
with a pediatric Satinsky’s clamp. The liver was resected, and the donor liver placed
orthotopically. Prior to implantation, the donor liver was flushed with 12 mL of cold lactated
Ringers solution. The SHVC, PV, and IHVC anastomoses were performed using the cuff
technique. The bile duct was reconstructed with an indwelling Teflon stent (I.D. 0.6 mm).
Recipients were administered a total of 7 mL of saline (0.45%): glucose (2.5%) mixture during
the surgery to compensate for fluid loss. Following transplantation, the animals were allowed
to recover under a heating lamp and had free access to food and water. There were no significant
differences in duration of cold preservation (<40 min) and portal venous clamping time (<18
min) among groups.

NIH-PA Author Manuscript

Experimental Design
The effects of MP (sodium succinate), its liver-targeted dextran 70 kD prodrug (DMP) (16),
or vehicle (saline) on recipient survival, allograft rejection, and splenocyte proliferation were
evaluated in three separate experiments. In all experiments, recipients were administered a
single 5-mg/kg (MP equivalent) dose of either MP or DMP or an equal volume of saline via
penile vein.
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In the first transplanted set, drugs or vehicle were administered immediately following the
transplantation, and the recipients were monitored every day for survival. In the second
experiments, the transplanted rats were injected with drugs or vehicle, and five and nine days
following transplantation, a subset of recipients from each group was euthanized. Blood (~ 500
μL) was collected from the tail vein on days 2, 4, and 5 in the recipients euthanized on day 5,
and on days 3, 6, and 9 in the recipients euthanized on day 9. Plasma was immediately separated
and stored at −20°C until further analysis. A portion of the liver grafts from recipients
euthanized on days 5 or 9 was immersed in 10% (v/v) neutral-buffered formalin for subsequent
histological analysis. A second portion of the liver was frozen immediately at −20°C for
biochemical analysis. Finally, in the third set of experiments, nine days after the injection of
vehicle, MP, or DMP, naïve Lewis rats were euthanized and spleen was removed for splenocyte
proliferation assay.
Analysis of Plasma Liver Function Markers
Plasma levels of ALT, AST, ALP, and bilirubin were estimated spectrophotometrically using
commercially available kits (Teco Diagnostics, Anaheim, CA). Blood glucose was measured
with an automated analyzer (Onetouch Ultra®, Lifescan, Inc, Milpitas, CA).

1This work was supported in part by an unrestricted research fund generated from research contracts to RM and by a grant from the
National Institute of General Medical Sciences of NIH (R01 GM069869-01A2).
Transplantation. Author manuscript; available in PMC 2006 June 27.
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Allograft Histology
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Formalin-fixed samples were embedded in paraffin and subsequently stained with hematoxylin
and eosin. A pathologist (D.L.M.), who was blinded to the treatment groups, graded rejection
using the Banff Rejection Activity Index (RAI) (23).
Cytokine Analysis in Plasma and Liver
The concentrations of TNF-α and IL-2 were measured in both plasma and liver extracts. The
liver extracts were prepared in a protease inhibitor cocktail according to the manufacturer’s
(Sigma Chemical Co., St. Louis, MO) instructions. The concentrations of TNF-α and IL-2 in
the plasma and those of IL-2 in the liver extracts were quantified using ELISA (Biosource
International, Inc., Camarillo, CA). The concentrations of TNF-α in the liver extracts were
measured using the established cytotoxicity of TNF-α against murine L929 cells (NCTC clone
929; American Type Culture Collection, Manassas, VA). Briefly, after overnight incubation
of the cells (2 x 104/well) in 96-well microplates, standards containing rat TNF-α (PeproTech,
Rocky Hill, NJ) or diluted liver extracts were added to the wells in a media containing 4 μg/
ml actinomycin D. After an overnight incubation and subsequent decanting of samples and
rinsing the wells with the media, the viability of the cells was determined using the CellTiter
96 Aqueous Non-Radioactive Proliferation Assay (Promega Corporations, Madison, WI).
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Alloantibody Response
The donor-specific IgM alloantibody response in recipient rats was determined using sera from
9-day transplanted rats by flow cytometry. Peripheral blood mononuclear cells (PBMCs)
obtained from donor DA blood by cardiac puncture were isolated on a Lympholyte R density
gradient (Cedarlane Laboratories, Ontario, Canada). Diluted (1:10) serum from Control-, MP-,
and DMP-treated rats was incubated with the donor PBMCs (1 x 106 cells). After washing, the
cells were stained with FITC conjugated mouse anti-rat IgM monoclonal antibody (clone:
HIS40; eBioscience, San Diego, CA) and analyzed using a FACScan (Beckton-Dickinson,
CA).
Splenocyte Proliferation
Spleen lymphocytes were prepared as described before (24). Briefly, the cells (2 x 105) were
incubated in the presence of bacterial lipoplysaccharide (LPS, 10 μg/ml) (Sigma Chemical Co.,
St. Louis, MO) for 66 hr, and during the last 18 hr, 0.5 μCi of tritiated thymidine was added.
After harvesting, the cells were counted using a Beckman LS 6500 Counter.
Statistical Analysis
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The statistical evaluation of differences in recipient survival was performed using the log rank
test applied to Kaplan-Meier plots. All other statistical comparisons among groups were
conducted using ANOVA with subsequent Dunnett’s post-hoc analysis. All tests were
conducted at significance level of 0.05. Data are presented as mean ± S.D.

RESULTS
Effects of MP and DMP on Recipient Survival
The plot of percent survival as a function of post-transplantation time for Control, MP, and
DMP groups is shown in Fig. 1. All untreated Control recipients died on or within day 12, with
a mean survival time (MST) of 10.5 days (range, 9–12 days). As expected, a single
subtherapeutic dose (5 mg/kg) of MP did not significantly prolong allograft survival, as
recipients in this group died within day 12, with a MST of 11 days (range, 10–12 days).
However, a single dose (5 mg/kg, MP equivalent) DMP treatment significantly (P<0.05)
prolonged recipient survival with a MST of 27.8 days (range, 14–60 days).
Transplantation. Author manuscript; available in PMC 2006 June 27.
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Effects of MP and DMP on Acute Allograft Rejection
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Plasma liver function markers—The plasma bilirubin levels as a function of posttransplantation time for Control, MP, and DMP groups are shown in Fig. 2 (top panel). In
general, plasma bilirubin increased with post-transplantation time, with maximum levels
observed on day 9. Whereas DMP treatment significantly (P<0.05) decreased (range, 50–80%
inhibition compared with Control) the acute rejection-mediated elevation of plasma bilirubin
from day 3 to 9, the effects of MP on bilirubin levels were significant only on day 3 (Fig. 2,
top).
The plasma ALP levels as a function of post-transplantation time and treatment are also shown
in Fig. 2 (bottom panel). Similar to the bilirubin levels (Fig. 2, top), plasma ALP levels tended
to increase with post-transplantation time, with maximum levels observed on day 9. DMP
treatment significantly (P<0.05) decreased (range, 40–60% inhibition compared with Control)
the rejection-mediated increase in the plasma ALP levels from day 2 to 6 post-transplantation.
However, a subsequent lack of inhibition was observed on day 9 (Fig. 2, bottom). As for MP,
the ALP levels were reduced only on day 2 with this treatment (Fig. 2, bottom).
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The plasma concentrations of AST and ALT in different treatment groups on days 5 and 9 posttransplantation are shown in Fig. 3. Only on day 9, both MP and DMP significantly (P<0.05)
decreased (~52 and 58%, respectively) the plasma ALT levels, compared with Control group
(Fig. 2, bottom). Plasma AST levels were, however, significantly (P<0.05) decreased (~53%)
only by DMP treatment on day 9 (Fig. 3, top).
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Allograft histology—Representative images of liver allografts on days 5 and 9 in Control,
MP, and DMP groups are shown in Fig. 4. In untreated allografts on day 5 (Fig 4, A), marked
expansion of most of the portal triads by a mixed leukocytic infiltrate, characteristic of
rejection, was prominent, with inflammatory spillover into periportal parenchyma. Bile ducts
contained a variable leukocytic infiltrate and were lined by disorganized epithelium having a
high nucleus to cytoplasm ratio. Evidence of endothelitis (subendothelia leukocytic infiltrates)
and perivenous inflammation was extensive in portal as well as sublobular veins (Fig 4, A).
Inflammation around sublobular veins was prominent and extended into perivenous hepatic
parenchyma. In the MP group on day 5 (Fig. 4, B), the histological lesions of rejection were
very similar to those in the saline-treated recipients (Fig. 4, A). In the DMP group on day 5,
lesions were less severe (Fig 4, C). Some, but not the majority of portal triads, were expanded
by a mixed infiltrate of lymphocytes, lymphoblasts, and few neutrophils and eosinophils.
However, there was little to no extension into periportal hepatic parenchyma. Few bile ducts
contained a leukocytic infiltrate, and changes in biliary epithelial cells were mild. Mild
inflammation of some soblobular veins was noted, and the infiltrate did not extend into
perivenous parenchyma in this group (Fig. 4, C).
On day 9, the Control (Fig. 4, D) and MP (Fig. 4, E) group allografts demonstrated similar
histological signs of rejection as seen on day 5 (Fig. 4, A and B, respectively). In the DMP
group, the infiltration drastically increased from day 5 (Fig. 4, C) to day 9 (Fig. 4, F), with no
apparent difference among the three treatment groups on day 9 (Fig. 4).
The semi-quantitative evaluation of allograft rejection for all the livers harvested on day 5 is
shown in Table 1. Whereas the portal, bile duct, and venous endothelial inflammatory indices
were, respectively, ranked severe, moderate, and severe for both the vehicle and MP-treated
groups, the respective indices were reduced to moderate, mild, and mild after the DMP
treatment (Table 1). Consequently, overall RAI in the DMP group (3.8 ± 0.5) was significantly
(p<0.05) lower (~50%) than that in both the Control and MP groups (Table 1). In contrast to
the data for day 5, most of the inflammatory indices on day 9 were severe and not significantly
affected by the treatments (data not shown).
Transplantation. Author manuscript; available in PMC 2006 June 27.

Chimalakonda et al.

Page 6

NIH-PA Author Manuscript

Plasma and hepatic cytokines—Plasma and hepatic concentrations of TNF-α and IL-2
proteins on days 5 and 9 are shown in Fig. 5. Plasma TNF-α levels significantly decreased in
Control recipients from day 5 to day 9. In terms of treatment effect, only DMP significantly
(P<0.05) decreased plasma TNF-α protein levels (~85 % inhibition, compared with Control
group) on day 5. The TNF-α profiles in the liver tissue were qualitatively similar to those in
the plasma in that only DMP treatment in the 5-day group resulted in a significant (P<0.05)
decline in the hepatic TNF-α levels. In contrast, treatment with MP did not have any significant
effect on either plasma or hepatic TNF-α levels (Fig. 5, left panels).
The plasma and hepatic concentrations of IL-2 protein were unaltered by post-transplantation
time or treatment (Fig. 5, right panels).
Alloantibody response—The IgM alloantibody responses on day nine after transplantation
are shown in Figure 6A for vehicle (Control)-, MP-, and DMP-treated rats. Whereas MP
treatment did not alter the IgM response, the DMP-treatment resulted in a 46% decline in mean
channel fluorescence, compared with untreated animals.
Effect of MP and DMP on Splenocyte Proliferation
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Methylprednisolone treatment did not change the LPS-induced proliferation of spleen
lymphocytes nine days after drug injection (Fig. 6B). However, DMP treatment inhibited this
parameter by ~60% (Figure 6B).

DISCUSSION
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Large intravenous doses of MP (up to three 1-g pulses) are currently the first-line therapy for
management of acute cellular rejection in liver transplant patients (2). Although effective in
controlling acute rejection, this treatment has been fatal in a few cases (25–30) and/or
associated with severe life-threatening toxicities related to cardiovascular system (e.g., cardiac
arrest and arrhythmia) (27,29–31), central nervous system (e.g., seizure and blindness) (25,
32–35), severe infections (both viral and bacterial) (36–39), and metabolic complications (e.g.,
hypokalemia) (40). Except for infections, these toxicities are mainly related to the extensive
extra-hepatic distribution of MP to organs like heart, lung, and brain. Therefore, selective
delivery of MP to the liver may increase the allograft exposure to the drug, improving graft
function, while decreasing systemic drug exposure. This strategy may allow administration of
lower doses of the drug, reducing toxicity without sacrificing efficacy. Indeed, our current
results in an OLT model show that a single 5-mg/kg dose of the liver-targeted dextran prodrug
(DMP) significantly decreases liver allograft rejection (Fig. 4 and Table 1) and enhances graft
survival (Fig. 1). In contrast, treatment with equimolar doses of the parent drug MP resulted
in acute allograft rejection and recipient survival similar to those in untreated animals (Figs. 1
and 4 and Table 1).
Allograft rejection, as assessed by plasma bilirubin and ALP levels (Fig. 2) and liver histology
(Fig. 4 and Table 1), was ameliorated significantly only by DMP treatment. This advantage
over the parent drug MP is most likely due to the prodrug’s unique pharmacokinetic and
pharmacodynamic properties (17,20). Our previous studies in rats (17) demonstrated that ~30%
of the DMP dose accumulates in the liver and gradually regenerates the active drug (MP) for
days. This is in contrast to a maximum of only ~4% of the dose found in the liver following
MP dosing, which rapidly declines to below detection levels in few hours (17). Furthermore,
this selective accumulation resulted in the prodrug having a more intense and sustained local
(hepatic) immunosuppressive activity after systemic administration of the equivalent doses of
DMP or MP to rats (20); the area under the effect-time curve, as measured by the inhibition of
bacterial endotoxin-induced TNF-α release in ex vivo perfused livers, was ~ 4 fold greater after
the injection of DMP than after MP injection (20). Therefore, the superiority of DMP over MP
Transplantation. Author manuscript; available in PMC 2006 June 27.
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observed in our current studies with the OLT model is partly due to the selective accumulation
of DMP in the liver, resulting in a gradual regeneration of the active drug (MP).
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Besides induction of local immunosuppression in the liver, DMP also inhibits immune
responses in the spleen (19). Previous studies in our laboratory (17,19) have shown that, in
addition to the liver, DMP accumulates in the spleen, where it regenerates the active drug MP.
Moreover, the inhibition of concanavalin A-induced splenocyte proliferation by DMP was both
more intense and sustained than that by an equimolar dose of MP (maximum inhibition of
100% at 24 hour vs. 50% inhibition at 2 hour, for DMP and MP, respectively) (19). However,
the splenocyte proliferation returned to baseline values within 48 hr after drug administration.
Because Concanavalin A and LPS mainly stimulate T cells and B cells (41), respectively, we
used LPS in our current study to determine the effects of our conjugate on the proliferation of
B cells. As demonstrated in the results (Fig. 6B), DMP treatment caused a significant reduction
in the LPS-induced splenocyte proliferation nine days after transplantation. Therefore, the
effect of DMP on B lymphocytes appears to be longer lasting than those for the T cells.
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The LPS-induced decrease in splenocyte proliferation (Fig. 6B) in DMP-treated transplanted
rats was associated with a decrease in IgM alloantibodies (Fig. 6A). In agreement with our
studies (Fig. 1), previous studies (42) have also shown a correlation between the steroidinduced reduction in IgM alloantibodies and increased survival. Our data further shows a
correlation between inhibition of LPS-induced splenocyte proliferation and alloantibody
levels, suggesting that B cells may contribute to the liver allograft rejection. Nevertheless, the
observed reduction in alloantibody levels and in the LPS-stimulated splenocytes in DMPtreated rats (Fig. 6) suggests that the systemic immunosuppressive activity of DMP contributes,
at least in part, to its overall effects.
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Our observation that a single 5-mg/kg dose of MP is ineffective in preventing acute rejection
in an OLT model is not surprising. This dose of MP is considered subtherapeutic because even
at doses much higher than 5 mg/kg, MP did not improve recipient survival in a high-responder
OLT model (43). Wang et al. (43) reported the effects of a 5-day course of MP treatment on
liver transplant recipient survival in a rat acute rejection model. Recipients were administered
a 16-mg/kg i.v. dose of MP (~ 3 times the dose used in our study) following OLT, and the dose
was tapered by half for the next 4 days post-transplantation. They reported a lack of significant
difference in survival between the MP-treated and untreated recipients (43). Although a single
dose local immunosuppression prolonged allograft survival in our study (Fig. 1), systemic
immunosuppression with MP for a longer duration (5 days) and at a higher dose did not (43).
Therefore, local immunosuppression in the liver via dextran conjugation may be considered
as a method to decrease total dose of immunosuppressive agents while still preventing allograft
rejection.
Although administered as a single dose, immunosuppressive activity of DMP was sustained
for at least five days after the transplantation. Allograft rejection in the DMP group was
attenuated at least until day 5 (Fig. 4 and Table 1), following which the lymphocytic infiltration
returned to control levels by day 9 (Fig. 4). In addition, the plasma ALP (Fig. 2) and plasma
and liver TNF-α (Fig. 5) concentrations also demonstrated a similar trend. Therefore, the
observed improvement in survival (Fig. 1) in the DMP group may be, in part, due to the
prevention of allograft rejection during the initial week. Although the single dose treatment
did not provide long-term survival (i.e., >100 days) in our study, it is likely that long-term
survival may be achieved by a multiple dosing regimen of the prodrug. Nevertheless, the
present single dose study represents a foundational step in the design and conduct of future
multiple dose investigations.

Transplantation. Author manuscript; available in PMC 2006 June 27.
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Corticosteroids exert a broad range of actions on the immune system, including alterations in
the synthesis of various cytokines (36,44). Reduction of plasma and hepatic TNF-α (Fig. 5)
may be responsible, at least in part, for the improvement in allograft rejection and survival
observed in our study. Plasma TNF-α levels are elevated in patients with allograft rejection
(45), and anti-TNF-α antibodies reportedly (46) decrease rejection and improve survival in
animal models. Attenuation of plasma TNF-α may decrease adhesion molecule expression on
the sinusoidal endothelial cells (47), resulting in a decrease in allograft infiltration, observed
in our study on day 5 (Fig. 4 and Table 1). Additionally, because TNF-α is cytotoxic (48), a
DMP-induced decrease in its intrahepatic concentrations, observed in our studies (Fig. 5), is
expected to decrease the graft injury, an observation consistent with the lower levels of the
hepatic injury markers like ALT and AST in the DMP group (Fig. 2). Although corticosteroids
are known (36) to decrease the production of another major cytokine interleukin (IL)-2, we did
not notice any alterations in IL-2 protein levels in plasma or the graft (Fig. 5). Therefore, plasma
and intrahepatic inhibition of TNF-α may explain some of the beneficial effects of DMP.
However, the complete mechanism of action of DMP needs further evaluation.
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Other investigators have tested carriers such as liposomes for selective delivery of
immunosuppressive agents to the liver. Friese et al. (8) and Ko et al. (9) reported the use of
cyclosporine and tacrolimus incorporated liposomes, respectively, in animal models of liver
transplantation. Both of these studies (8,9) demonstrated improvement in survival in the
liposome-treated groups, compared with the free drug. Although liposomes are promising, they
have limitations such as short stability and relatively limited drug load. The latter may require
injection of more than acceptable lipid loads (49), especially in patients with acute rejection
requiring high dose corticosteroids. The dextran prodrug reported here is an alternative to
liposomes for local immunosuppression of the allograft following liver transplantation.
In addition to our studies on neutral dextran prodrugs of MP, synthesis and in vivo
pharmacokinetics of a negatively-charged dextran-tacrolimus conjugate was reported by Yura
et al. (50). These authors (50) showed that conjugation caused a significantly higher drug
exposure in plasma, associated with only modest increases in the liver and spleen accumulation.
The lower accumulation of tacrolimus conjugate in spleen and liver, compared with our MP
conjugate, is most likely due to the negative charge of dextrans used in their study, which
reportedly (51) decreases tissue accumulation. Nonetheless, our study is the first to examine
the immunosuppressive efficacy of dextran conjugates in an animal allograft model.
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In conclusion, selective delivery of MP to the liver as a dextran prodrug significantly improved
allograft survival and decreased acute rejection in a rat OLT model. To our knowledge, this it
the first study demonstrating the therapeutic applicability of macromolecular/polymer based
prodrugs in an organ transplantation model. Dextran conjugation of immunosuppressive drugs
may represent a potential technique to enhance efficacy of these agents in liver transplant
patients.
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FIGURE 1.

Percent survival curve of LEW recipients of DA liver allografts. Recipients were treated with
a single 5-mg/kg i.v. dose of MP or DMP or with saline (Control) on day 0 (n=4/group). Mean
survival times (MST) in Control, MP, and DMP groups are 10.5, 11, and 27.5 days, respectively
(P<0.05 for DMP vs. Control or MP).
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FIGURE 2.

Plasma bilirubin (top) and ALP (bottom) concentrations in LEW recipients of DA liver
allografts. Recipients were treated with a single 5-mg/kg i.v. dose of MP or DMP or with saline
(Control) on day 0. Columns and bars represent mean and SD values, respectively (n=4/group).
*, Significantly different (P<0.05) from Control.
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FIGURE 3.

Plasma AST (top) and ALT (bottom) concentrations on the 5th and 9th post-transplantation
days in LEW recipients of DA liver allografts. Recipients were treated with a single 5-mg/kg
i.v. dose of MP or DMP or with saline (Control) on day 0. Columns and bars represent mean
and SD values, respectively (n=4/group). *, Significantly different (P<0.05) from Control.
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FIGURE 4.

Representative hematoxylin-eosin stained liver sections on the 5th (left column) and 9th (right
column) post-transplantation days in LEW recipients of DA liver allografts. Recipients were
treated with saline (A and D) or a single 5-mg/kg i.v. dose of MP (B and E) or DMP (C and
F) on day 0.
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FIGURE 5.

TNF-α and IL-2 protein concentrations in the plasma (top panel) and liver (bottom panel) on
the 5th and 9th post-transplantation days in LEW recipients of DA liver allografts. Recipients
were treated with a single 5-mg/kg i.v. dose of MP or DMP or with saline (Control) on day 0.
Columns and bars represent mean and SD values, respectively (n=4/group). *, Significantly
different (P<0.05) from Control.
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FIGURE 6.
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Top Panel: Donor (DA)-specific IgM alloantibody response (mean channel fluorescence) in
the 9-day sera of recipient (Lewis) rats treated with a single 5-mg/kg i.v. dose of MP or DMP
or with saline (Control) on day 0 (n=4/group), quantitated using flow cytometry. Bottom Panel:
Splenocyte proliferation (count per minute) in naïve Lewis rats treated with vehicle (Control)
or a single 5 mg/kg dose (MP equivalent) of MP or DMP 9 days before spleen harvest (n=3/
group). Columns and bars represent mean and SD values, respectively. *, Significantly
different (P<0.05) from Control.
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TABLE 1

Semi-quantitative assessment of histological grade of acute rejection
Category

Treatment
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Portal Inflammation
Bile Duct Inflammation
Venous Endothelial
Inflammation
Rejection Activity Index
(RAI)

Control

MP

DMP

3.0 ± 0.0 (Severe)a
1.8 ± 0.5 (Moderate)
2.8 ± 0.5 (Severe)

3.0 ± 0.0 (Severe)
1.8 ± 0.5 (Moderate)
2.5 ± 0.6 (Severe)

1.8 ± 0.5b (Moderate)
1.0 ± 0.0 (Mild)
1.0 ± 0.0b (Mild)

7.5 ± 0.6

7.3 ± 1.0

3.8 ± 0.5b

Rejection grading was based on Banff criteria (Ref (23) in liver allografts on day 5 following OLT. Recipients were treated with a single 5-mg/kg i.v.
dose of MP or DMP or with saline (Control) on day 0.
a

Key: 3, severe; 2, moderate; 1, mild.

b

p<0.05 Compared to Control and MP groups.

NIH-PA Author Manuscript
NIH-PA Author Manuscript
Transplantation. Author manuscript; available in PMC 2006 June 27.

